The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
 
Cristiano Ferrario
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Knight Pharmaceuticals; Merck; Novartis; Pfizer; Roche Canada
Consulting or Advisory Role - AstraZeneca; Bayer; Merck; Novartis; Roche; Seagen
Speakers' Bureau - AstraZeneca; Knight Therapeutics; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer; Bicycle Therapeutics (Inst); Immunomedics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Zymeworks (Inst)
Expert Testimony - Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Novartis; Roche
 
Josep M. Piulats
Consulting or Advisory Role - Astellas Pharma; BeiGene; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck Sharp & Dohme; Roche/Genentech; VCN Biosciences
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Incyte; Janssen Oncology; Merck Sharp & Dohme; Pfizer/EMD Serono
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen Oncology; Roche
 
Mark David Linch
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BioNTech; Bristol-Myers Squibb; Janssen Oncology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - bristol myers squibb; Janssen; MSD
 
Michael Stoeckle
No Relationships to Disclose
 
Brigitte Laguerre
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Ipsen; Ipsen; Janssen-Cilag; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Janssen Oncology; Novartis; Pfizer; pfizer; Pfizer
 
José A. Arranz
Consulting or Advisory Role - Astellas Pharma; EUSA Pharma; Janssen; Merck; MSD; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Roche
 
Tilman Todenhöfer
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Basilea; Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Janssen; Lilly; Merck; MSD; Pfizer; RhoVac; Roche; Sanofi
 
Peter C.C. Fong
Consulting or Advisory Role - MSD
Travel, Accommodations, Expenses - Pfizer
 
William R. Berry
Honoraria - AstraZeneca; Dendreon; Genomic Health; Janssen Oncology; Merck; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca; Genomic Health; Janssen Oncology; Merck; Merck; Pfizer
Speakers' Bureau - Dendreon
Research Funding - Merck (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Genomic Health; Janssen Oncology; Merck; Pfizer
 
Urban Emmenegger
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Knight Therapeutics; Merck
Research Funding - Astellas Pharma; Bayer; Janssen
 
Loic Mourey
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; janssen; Pfizer; Sanofi
 
Nataliya Mar
Speakers' Bureau - Astellas Pharma; Seagen
 
Leonard Joseph Appleman
Consulting or Advisory Role - AADi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Surface Oncology (Inst)
Other Relationship - Pfizer
(OPTIONAL) Uncompensated Relationships - Exelixis
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Henry Jacob Conter
Employment - Roche Canada
Honoraria - Bristol-Myers Squibb; Celgene; Janssen Oncology; Merck; Novartis
Consulting or Advisory Role - Lilly; Roche Canada
 
Xin Tong Li
Employment - MSD
 
Charles Schloss
Employment - Merck
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Evan Y. Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Clovis Oncology; Exelixis; Janssen; Merck
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)